Utibapril

Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities.

Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE)

Research Areas >> Cardiovascular Disease

Utibapril significantly inhibits plasma, renal, and vascular ACE but not ventricular ACE activity. Utibapril (2 μg/kg/day) significantly inhibits vascular ACE activity, and Utibapril (250 μg/kg/day) results in a significant inhibition of plasma ACE. Furthermore, angiotensin I-induced decreases in coronary flow in the isolated heart are significantly inhibited after treatment with the higher doses of utibapril[1]. FPL 63547 is rapidly and extensively excreted as the diacid in the bile but appeared in the urine in negligible amounts[2].

[1]. Buikema H, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91.

[2]. Carr RD, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol. 1990 May;100(1):90-4.

Angiotensin I/II (1-7) trifluoroacetate salt | Captopril | Enalapril maleate | Perindopril erbumine | Lisinopril diydrate | Phosphoramidon disodium salt | Trandolapril | Fosinopril sodium | Quinapril hydrochloride | Ramipril | Cilazapril Monohydrate | Enalaprilat Dihydrate | omapatrilat | Temocapril (hydrochloride) | Hemorphin-7